...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >FORMULATION, OPTIMIZATION AND EVALUATION OF ENROFLOXACIN SOLID LIPID NANOPARTICLES FOR SUSTAINED ORAL DELIVERY
【24h】

FORMULATION, OPTIMIZATION AND EVALUATION OF ENROFLOXACIN SOLID LIPID NANOPARTICLES FOR SUSTAINED ORAL DELIVERY

机译:缓释口服恩诺沙星固体脂质纳米粒的配方,优化和评价

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The objective of the present study was to formulate and evaluate enrofloxacin SLNs using a hot homogenization coupled with ultrasonication method. The SLNs were prepared using tripalmitin as lipid carrier, tween 80 and span 80 as surfactants and poly vinyl alcohol (PVA) as a stabilizer. The influence of factors such as concentration of lipid carrier, composition and concentration of surfactant on the particle size were investigated to optimize the formulations. The optimized SLNs formulations were utilized to entrap 0.1% enrofloxacin and characterized for particle size, polydispersity index, zeta potential (using dynamic light scattering), shape (using atomic force microscopy and transmission electron microscopy), drug encapsulation efficiency (using by dialysis and ultracentrifugation methods), and in vitro drug release (using by dialysis). The prepared SLNs were analyzed by FT-IR spectroscopy to confirm the cross-linking reaction between drug, lipid and surfactants. The results demonstrated that the particle size, polydispersivity index, zeta potential, encapsulation efficiency and loading capacity of the SLNs were 154.72± 6.11nm, 0.42±0.11, -28.83±0.60mV, 59.66±3.22% and 6.13±0.32%, respectively. TEM and AFM images showed spherical to circular particles with well defined periphery. In vitro drug release exhibited biphasic pattern with an initial burst release of 18% within 2h followed by sustained release over 96h. FT-IR study suggested that during the process of formulations, lipid and surfactants have not reacted with the drug to give rise to reactant products and it was only physical mixture.
机译:本研究的目的是使用热均质结合超声方法来配制和评估恩诺沙星SLN。 SLNs是使用三棕榈精蛋白作为脂质载体,吐温80和span 80作为表面活性剂以及聚乙烯醇(PVA)作为稳定剂来制备的。研究了脂质载体浓度,组成和表面活性剂浓度等因素对粒径的影响,以优化配方。经过优化的SLNs配方可截留0.1%的恩诺沙星,并对其粒径,多分散指数,ζ电位(使用动态光散射),形状(使用原子力显微镜和透射电子显微镜),药物封装效率(通过透析和超速离心使用)进行表征方法)和体外药物释放(通过透析使用)。通过FT-IR光谱分析所制备的SLN,以确认药物,脂质和表面活性剂之间的交联反应。结果表明,SLN的粒径,多分散指数,ζ电势,包封效率和负载能力分别为154.72±6.11nm,0.42±0.11,-28.83±0.60mV,59.66±3.22%和6.13±0.32%。 TEM和AFM图像显示球形到圆形颗粒,外围轮廓清晰。体外药物释放表现出双相模式,在2h内首次爆发释放为18%,随后在96h内持续释放。 FT-IR研究表明,在配制过程中,脂质和表面活性剂并未与药物反应而产生反应产物,而只是物理混合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号